Oral COVID-19 vaccine being developed by one of LA Lakers owners

Could a PILL prevent COVID-19? An oral vaccine that might also protect against coronavirus variants is being developed by an owner of the LA Lakers

• Dr Patrick Soon-Shiong, part-owner of the Los Angeles Lakers, is working to develop an oral COVID-19 vaccine
• Researchers of the Chan Soon-Shiong Research Institute say all three vaccines  target the spike protein the virus uses to enter cells
• The new vaccine targets the globe-like shape in the middle of the virus, which the team says is not prone to mutation
• Additionally, the pill would not just generate neutralizing antibodies but also T cells, which are types of white blood cells that bind to and kill viruses
• Soon-Shiong’s team says the oral vaccine would be faster, cheaper and easier to distribute, as well as provide more long-lasting protection 

One of the owners of the Los Angeles Lakers is developing a coronavirus vaccine that would not require an injection.

Dr Patrick Soon-Shiong and his team of researchers are testing whether oral pills could work in conjunction with – or even better than – vaccines approved by the Food and Drug Administration, reported CBS Los Angeles.

All three vaccines authorized for emergency use in the U.S. – from Pfizer-BioNTech, Moderna and Johnson & Johnson – work by creating antibodies that neutralize the spike protein that the coronavirus uses to enter and infect human cells.

But the team’s new vaccine targets the globe-like shape in the middle of the virus, which does not often mutate. 

In addition, the team says that the vaccine would be faster, cheaper and easier to administer because it wouldn’t have to be stored at refrigerator or freezing temperatures.  

Researchers of the Chan Soon-Shiong Research Institute are developing a new oral COVID-19 vaccine (above) that targets the globe-like shape in the middle of the virus

One of the developers, Dr Patrick Soon-Shiong (pictured), part-owner of the Los Angeles Lakers, says the new vaccine would also generate T cells, which bind to and kill viruses

‘To have a vaccine that’s room temperature, that could be a pill, is life changing,’ one of the investigators, Dr Tara Seery, of the Chan Soon-Shiong Research Institute for Medicine, in El Segundo, California told CBS Los Angeles.

For the trial, which is currently in Phase I, the team split volunteers into four groups to see how well the pills work.

One group received just pills, the second group received just an injection, the third group received pills and an injection and the fourth received neither.

The new oral vaccine also targets a part of the coronavirus that is less prone to mutation.

The majority of the most commonly recognized variants, including from the UK, South Africa and Brazil – have mutations affecting the virus’s spike protein.

This protein is what the coronavirus uses to ‘hijack’ human cells, make multiple copies of itself and spread throughout the body. 

But the new oral vaccine attacks the center of the virus known as the lipid bilayer envelope, to which the spike protein is anchored.

‘And the value of doing so is that we generate killer T cells,’ Soon-Shiong told CBS Los Angeles. 

T cells are types of white blood cells that bind to and kill viruses.

The team believes that by generating both antibodies and T cells, recipients would have protection that lasts for a long time. 

An average of about three million adults are being vaccinated every day, with single-day totals reaching four million over the weekend.

Currently, 108.3 million Americans – 32.6% of the population – have received at least one dose and 63 million – 19% – are fully immunized

Soon-Chong says the researchers are also testing a combination of an injection and oral vaccines because he believes we may need both to beat back the virus. 

‘By giving a jab, we hope to develop T cells all around your body,’ he told the station. 

‘And by giving orally, we protect the mucus membranes, the gut and hopefully the nose, the mouth, because that’s how the virus comes in. It doesn’t come in through your blood.’  

The trial is open to adults between ages 18 and 55 who have never tested positive for COVID-19 and are not immunodeficient. Those who wish to sign up can visit here.

According to the Centers for Disease Control and Prevention, 108.3 million Americans – 32.6 percent of the population – have received at least one dose and 63 million – 19 percent – are fully immunized. 

An average of about three million adults are being vaccinated every day, with single-day totals reaching four million over the weekend. 

Source: Read Full Article